Development of new first-line therapeutic options for non-small-cell lung cancer

Lung Cancer

Volumn 54, Issue SUPPL. 2, 2006, Pages

  Crinò, Lucio ^a   Foglietta, Jennifer ^a   Hamzaj, Alketa ^a  

^a Perugia Hospital   (Italy)

Author keywords

Combination; First line; Monotherapy; NSCLC; Pemetrexed; Platinum; Toxicity; ZD6474

Indexed keywords

BEVACIZUMAB; BEXAROTENE; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VANDETANIB;

ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DEATH; DRUG EFFICACY; DRUG TOXICITY; HAIR LOSS; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MORTALITY; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CYTOTOXINS; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 33750621505     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.09.013     Document Type: Article

References (45)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Haus B.M., Razavi H., and Kuschner W.G. Occupational and environmental causes of bronchogenic carcinoma. Curr Opin Pulm Med 7 (2001) 220-225
3. Alberg A.J., and Samet J.M. Epidemiology of lung cancer. Chest 123 1S (2003) 21S-49S
4. Jemal A., Murray T., Wand E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. Ca cancer J Clin 55 (2005) 10-30
5. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
6. Bunn Jr. P.A., and Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4 (1998) 1087-1100
7. Jaakkimainen L., Goodwin P.J., Pater J., Warde P., Murray N., and Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 8 (1990) 1301-1309
8. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Kook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
9. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20 (2002) 4285-4291
10. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
11. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
12. Rudd R.M., Gower N.H., Spiro S.G., Eisen T.G., Harper P.G., Littler J.A., et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23 (2005) 142-153
13. Danson S., Middleton M.R., O'Byrne K.J., Clemons M., Ranson M., Hassan J., et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer 98 (2003) 542-553
14. Grigorescu A.C., Draghici I.N., Nitipir C., Gutulescu N., and Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 37 (2002) 9-14
15. Thomas P., Robinet G., Ferri-Dessens R.M., Lena H., Gouva S., Vernejoux J.M., et al. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Francais de Pneumo-Cancerologie Study. Lung Cancer 36 (2002) 191-198
16. Sederholm C. Gemcitabine versus gemcitabine plus carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol 29 9S (2002) 50-54
17. Cullen M.H., Billingham L.J., Woodroffe C.M., Chetiyawardana A.D., Gower N.H., Joshi R., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17 (1999) 3188-3194
18. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
19. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
20. Clarke S.J., Abratt R., Goedhals L., Boyer M.J., Millward M.J., and Ackland S.P. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13 (2002) 737-741
21. Rusthoven J.J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17 (1999) 1194
22. Manegold C., Gatzemeier U., von Pawel J., Pirker R., Malayeri R., Blatter J., et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 11 (2000) 435-440
23. Shepherd F.A., Dancey J., Arnold A., Neville A., Rusthoven J., Johnson R.D., et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92 (2001) 595-600
24. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
25. Scagliotti G.V., Kortsik C., Dark G.G., Price A., Manegold C., Rossell R., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11 (2005) 690-696
26. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
27. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21 (2003) 16-24
28. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., and Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23 (2005) 926-936
29. Kosmidis P.A., Kalofonos C., Syrigos K., Skarlos D., Fountzilas G., Nicolaides C., et al. Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC). J Clin Oncol 23 (2005) 7000 [abstract]
30. Treat J., Belani C.P., Edelman M.J., Socinski M.A., Ansari R.H., Obasaju C.K., et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1-99002L). J Clin Oncol 23 (2005) 7025 [abstract]
31. Rosell R., Scagliotti G., Danenberg K.D., Lord R.V., Bepler G., Novello S., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22 (2003) 3548-3553
32. Rosell R., Cobo M., Isla D., Massuti B., Montes A., Paz-Ares L., et al. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol 23 (2005) 7002 [abstract]
33. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4593-4599
34. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
35. Yuan A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., Luh K.T., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19 (2001) 432-441
36. Volm M., Koomagi R., and Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74 (1997) 64-68
37. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
38. Sandler A.B., Gray R., Brahmer J., Dowlati A., Schiller J.H., Perry M.C., et al. Randomised phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small-cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599. J Clin Oncol 23 (2005) LBA4
39. Laskin J.J., and Sandler A.B. First-line treatment for advanced non-small-cell lung cancer. Oncology (Williston Park) 19 (2005) 1671-1676 [discussion, pp. 1678-1680]
40. Herbst R.S., Johnson B.E., Rowbottom J.A., Fidias P., Lu C., Prager D., et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: Results of a randomized, placebo-controlled Phase II trial. Lung Cancer 49 2S (2005) S35. [abstract]
41. Blumenschein G.R., Khuri F., Gatzemeier U., Miller W.H., von Pawel J., Rigas J.R., et al. A randomised Phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 23 16S (2005) 7001 [abstract]
42. Jassem J., Zatloukal P., Ramlau R., Schwarzenberger S., Orlov, Rodrigues-Pereira J., et al. A randomized Phase III trial comparing bexarotene/cisplatin/vinorelbine versus cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol 23 16S (2005) 7024 [abstract]
43. Blumenschein G., Ludwig C., Thomas G., Tan E., Fanucchi M., Santoro A., et al. A randomized phase III trial comparing Ionafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy naive patients with advanced or metastatic non-small-cell lung cancer. Lung Cancer 49 2S (2005) S30 [abstract O-082]
44. Lynch T.J., Raju R., Lind M., Riviere A., Gatzemeier U., Drorr A., et al. Randomised Phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Proc Am Soc Clin Oncol 22 (2003) 2504 [abstract]
45. Paz-Ares L., Douillard J.Y., Koralewski P., Manegold C., Smit E.F., Reyes J.M., et al. Randomized Phase III trial of gemcitabine/cisplatin (GC) and protein kinase C a (PKCa) antisense oligonucleotide aprinocarsen in patients (pts) with advanced stage non-small cell lung cancer (NSCLC). J Clin Oncol 32 16S (2005) 7053 [abstract]